Children's Oncology Group's 2023 blueprint for research: Pediatric liver tumors

Liver tumors account for approximately 1%-2% of all pediatric malignancies, with the two most common tumors being hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Previous Children's Oncology Group studies have meaningfully contributed to the current understanding of disease pathophysiology and treatment, laying groundwork for the ongoing prospective international study of both HB and HCC. Future work is focused on elucidating the biologic underpinnings of disease to support an evolution in risk categorization, advancements in the multidimensional care required to treat these patients, and the discovery of novel therapies.

Automated summary

Liver tumors, including hepatoblastoma (HB) and hepatocellular carcinoma (HCC), account for 1%-2% of all pediatric malignancies. Previous studies by the Children's Oncology Group have significantly contributed to the current understanding of disease pathophysiology and treatment, laying the foundation for ongoing international research on HB and HCC. Future research aims to uncover the biological mechanisms underlying these tumors, improve risk stratification, advance multidimensional care, and discover novel therapies.